Table 1. Group A, Group B and Group U antibiogram susceptibility profile of A. baumannii isolated from urine samples [as per CLSI recommendations, 2012] .
| Suggested groupings M02 & M07 [Table 1A, CLSI, 2012] | Antimicrobial agent | Disc con-tent [in µg] | Zone Diameter Interpretive Crite-ria (nearest whole mm) | A. baumannii antibiogram pattern [n=73 (%)] | ||||
| S | I | R | S | I | R | |||
| Group A primary testing and report | Ampicillin-sulbactam | 10/10 | ≥15 | 12-14 | ≤11 | 0 (0) | 0 (0) | 73 (100) |
| Ceftazidime | 30 | ≥18 | 15-17 | ≤14 | 0 (0) | 0 (0) | 73 (100) | |
| Ciprofloxacin | 5 | ≥21 | 16-20 | ≤15 | 5 (6.84) | 8 (10.95) | 60 (82.19) | |
| Levofloxacin | 5 | ≥17 | 14-16 | ≤13 | 15 (20.54) | 22 (30.13) | 36 (49.31) | |
| Doripenem | 10 | ≥18 | 15-17 | ≤14 | 11 (15.06) | 17 (23.28) | 45 (61.64) | |
| Imipenem | 10 | ≥22 | 19-21 | ≤18 | 0 (0) | 0 (0) | 73 (100) | |
| Meropenem | 10 | ≥18 | 15-17 | ≤14 | 10 (13.69) | 14 (19.17) | 49 (67.12) | |
| Gentamicin | 10 | ≥15 | 13-14 | ≤12 | 6 (8.21) | 9 (12.32) | 58 (79.45) | |
| Tobramycin | 10 | ≥15 | 13-14 | ≤12 | 22 (30.13) | 10 (13.69) | 41 (56.16) | |
| Group B optional primary testing | Amikacin | 30 | ≥17 | 15-16 | ≤14 | 0 (0) | 0 (0) | 73 (100) |
| Piperacillin-tazobactam | 100/10 | ≥21 | 18-20 | ≤17 | 0 (0) | 0 (0) | 73 (100) | |
| Cefepime | 30 | ≥18 | 15-17 | ≤14 | 0 (0) | 0 (0) | 73 (100) | |
| Cefotaxime | 30 | ≥23 | 15-22 | ≤14 | 0 (0) | 0 (0) | 73 (100) | |
| Ceftriaxone | 30 | ≥21 | 14-20 | ≤13 | 6 (8.2) | 0 (0) | 67 (91.78) | |
| Doxycycline | 30 | ≥13 | 10-12 | ≤9 | 41 (56.16) | 18 (24.65) | 14 (19.71) | |
| Minocycline | 30 | ≥16 | 13-15 | ≤12 | 56 (76.71) | 12 (16.43) | 5 (6.84) | |
| Trimethoprim – suphamethoxa-zole | 1.25 / 23.75 | ≥16 | 11-15 | ≤10 | 4 (5.47) | 2 (2.73) | 67 (91.78) | |
| Group U supplementary for urine | Tetracycline | 30 | ≥15 | 12-14 | ≤11 | 0 | 17 (23.28) | 56 (76.71) |